MedDataX Logo

Anecortave Acetate in Patients With Open-angle Glaucoma

NCT ID: NCT00320203

Last Updated: 2012-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety, efficacy, and duration of effect of a single administration of Anecortave Acetate Depot for treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open-angle Glaucoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

open-angle glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anecortave Acetate 3 mg Depot

Single injection, anterior juxtascleral depot (AJD)

Group Type EXPERIMENTAL

Anecortave Acetate Sterile Suspension, 6 mg/mL

Intervention Type DRUG

Single injection, anterior juxtascleral depot (AJD)

Anecortave Acetate 15 mg Depot

Single injection, anterior juxtascleral depot (AJD)

Group Type EXPERIMENTAL

Anecortave Acetate Sterile Suspension, 30 mg/mL

Intervention Type DRUG

Single injection, anterior juxtascleral depot (AJD)

Anecortave Acetate 30 mg Depot

Single injection, anterior juxtascleral depot (AJD)

Group Type EXPERIMENTAL

Anecortave Acetate Sterile Suspension, 60 mg/mL

Intervention Type DRUG

Single injection, anterior juxtascleral depot (AJD)

Anecortave Acetate Vehicle

Single injection, anterior juxtascleral depot (AJD)

Group Type OTHER

Anecortave Acetate Vehicle

Intervention Type OTHER

Single injection, anterior juxtascleral depot (AJD)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anecortave Acetate Sterile Suspension, 6 mg/mL

Single injection, anterior juxtascleral depot (AJD)

Intervention Type DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

Single injection, anterior juxtascleral depot (AJD)

Intervention Type DRUG

Anecortave Acetate Sterile Suspension, 60 mg/mL

Single injection, anterior juxtascleral depot (AJD)

Intervention Type DRUG

Anecortave Acetate Vehicle

Single injection, anterior juxtascleral depot (AJD)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18 years of age or older with open-angle glaucoma.

Exclusion Criteria

* Patients with open-angle glaucoma with a pseudoexfoliation or pigment dispersion component.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Theresa Landry

Role: STUDY_DIRECTOR

Alcon Research

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C-04-62

Identifier Type: -

Identifier Source: org_study_id